Table 7. Exemplary Recruiting/Active Status Clinical Trials (Phases I–IV) Researching PEGylated Lipid Formulation Safety.
| clinical trial identifier | interventions | conditions | status |
|---|---|---|---|
| NCT03483038 | PEGylated Liposomal Irinotecan (Onivyde)/FOLFOX regimen | pancreatic cancer | recruiting |
| NCT05000216 | Comirnaty/Spikevax | SARS-CoV-2 | recruiting |
| NCT05029999 | PEGylated Liposomal Doxorubicin (Doxil) | breast cancer | recruiting |
| NCT05077254 | Comirnaty | SARS-CoV-2 | recruiting |
| NCT05388487 | PEGylated Liposomal All-Trans Retinoic Acid (HF1K16) | solid tumor | recruiting |
| NCT01210768 | PEGylated Liposomal Doxorubicin/Cyclophosphamide | breast cancer | active, not recruiting |
| NCT02839707 | PEGylated Liposomal Doxorubicin/Atezolizumab/Bevacizumab | ovarian, fallopian tube, and peritoneal cancer | active, not recruiting |
| NCT03088813 | PEGylated Liposomal Irinotecan (Onivyde)/Topotecan | lung cancer | active, not recruiting |
| NCT04715438 | Spikevax | SARS-CoV-2 | active, not recruiting |
| NCT05618548 | Comirnaty/Spikevax | SARS-CoV-2 | active, not recruiting |